OCS vs LENZ

Analysts rate Oculis Holding AG (OCS) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison.

The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Oculis Holding AG (OCS) delivered a total return of +220.

5%, compared to -72. 4% for LENZ Therapeutics, Inc. (LENZ). Over 10 years, the gap is even starker: OCS returned +220. 5% versus LENZ's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Oculis Holding AG (OCS) is the lower-risk stock at 0.

82β versus LENZ Therapeutics, Inc. 's 1. 78β — meaning LENZ is approximately 116% more volatile than OCS relative to the S&P 500. On balance sheet safety, LENZ Therapeutics, Inc. (LENZ) carries a lower debt/equity ratio of 0% versus 2% for Oculis Holding AG — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Oculis Holding AG grew EPS 28.

6% year-over-year, compared to -21. 8% for LENZ Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

LENZ Therapeutics, Inc.

(LENZ) is the more profitable company, earning -430. 3% net margin versus -125. 0% for Oculis Holding AG — meaning it keeps -430. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LENZ leads at -477. 5% versus -106. 7% for OCS. At the gross margin level — before operating expenses — LENZ leads at 97. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Oculis Holding AG (OCS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

82), +220. 5% 10Y return). LENZ Therapeutics, Inc. (LENZ) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OCS: +220. 5%, LENZ: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.